Evidence map›Paper›PMID 35584629›Full record

ArticleCell reports. Medicine2022

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.

Zejie Mei, Tao Yang, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Observational
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zejie MeiState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Tao YangDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Ying LiuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Yuanyuan GaoState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Zemin HouState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Qian ZhuangState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Dongyin HeState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Xuebin ZhangState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Qilong TanState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Xuyou ZhuDepartment of Pathology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Yingyi QinDepartment of Health Statistics, Second Military Medical University, No. 800 Xiangyin Road, Shanghai 200433, China.
Xi ChenDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Chengdang XuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Cuidong BianDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Xinan WangDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Chenyang WangDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Denglong WuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Shengsong HuangDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China. Electronic address: hssfline@tongji.edu.cn.
Zhenfei LiState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China. Electronic address: zhenfei.li@sibcb.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel strategies for prostate cancer therapy are required to overcome resistance to abiraterone and enzalutamide. Here, we show that increasing 3βHSD1 after abiraterone and enzalutamide treatment is essential for drug resistance, and biochanin A (BCA), as an inhibitor of 3βHSD1, overcomes drug resistance. 3βHSD1 activity increases in cell lines, biopsy samples, and patients after long-term treatment with enzalutamide or abiraterone. Enhanced steroidogenesis, mediated by 3βHSD1, is sufficient to impair enzalutamide function. In patients, accelerated abiraterone metabolism results in a decline of plasma abiraterone as disease progresses. BCA inhibits 3βHSD1 and suppresses prostate cancer development alone or together with abiraterone and enzalutamide. Daidzein, a BCA analog of dietary origin, is associated with higher plasma abiraterone concentrations and prevented prostate-specific antigen (PSA) increases in abiraterone-resistant patients. Overall, our results show that 3βHSD1 is a promising target to overcome drug resistance, and BCA suppresses disease progression as a 3βHSD1 inhibitor even after abiraterone and enzalutamide resistance.

Indexed as

Prostatic Neoplasms, Castration-ResistantAndrostenesBenzamidesDrug Resistance, NeoplasmHumansMaleNitrilesPhenylthiohydantoinabirateroneAndrostenesBenzamidesenzalutamideNitrilesPhenylthiohydantoin3βHSD1abiraterone metabolismandrogenbiochanin Adaidzeinenzalutamide resistanceprostate cancersteroidogenesis

Identifiers

PMID35584629
PMCPMC9133401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.